title: Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma.
abstract: A 48-year-old patient with IgA k multiple myeloma received a BMT from his HLA-matched sibling. After transplantation, the disease relapsed. Melphalan therapy followed by reinfusion of haemopoietic blood stem cells collected from the patient led to the improvement of the clinical status, although mixed chimerism and an elevated serum IgA persisted. Successful donor immunisation against an immunogenic preparation of the recipient monoclonal protein was performed before the infusion of donor T lymphocytes (DLI) into the patient. Ten weeks after the lymphocyte infusions, no monoclonal band was evidenced and donor complete chimerism was detected. The patient did not develop GVHD. Once complete remission was achieved, the idiotype vaccine was administered to the patient. Nineteen months after DLI, the patient remains in remission. Bone Marrow Transplantation (2000).
authors.affiliation: Department of Hematology, Clínica Puerta de Hierro, Universidad Autónoma de Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Cabrera
authors.forename: F
authors.initials: F
authors.lastname: Díaz-Espada
authors.forename: Y
authors.initials: Y
authors.lastname: Barrios
authors.forename: M
authors.initials: M
authors.lastname: Briz
authors.forename: R
authors.initials: R
authors.lastname: Forés
authors.forename: L
authors.initials: L
authors.lastname: Barbolla
authors.forename: I
authors.initials: I
authors.lastname: Sanjuán
authors.forename: C
authors.initials: C
authors.lastname: Regidor
authors.forename: F J
authors.initials: FJ
authors.lastname: Peñalver
authors.forename: M N
authors.initials: MN
authors.lastname: Fernández
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001782:Blood Donors; D016026:Bone Marrow Transplantation; D002678:Chimera; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006085:Graft Survival; D006801:Humans; D007114:Immunization; D007070:Immunoglobulin A / Q000276:immunology*; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D007145:Immunoglobulin kappa-Chains / Q000276:immunology*; D016219:Immunotherapy, Adoptive; D017710:Lymphocyte Transfusion; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D009194:Myeloma Proteins / Q000276:immunology*; D012074:Remission Induction; D016879:Salvage Therapy; D013601:T-Lymphocytes / Q000637:transplantation*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007070:Immunoglobulin A; D007130:Immunoglobulin Idiotypes; D007145:Immunoglobulin kappa-Chains; D009194:Myeloma Proteins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan